Comparing Revenue Performance: Zoetis Inc. or Pharming Group N.V.?

Zoetis vs. Pharming: A Decade of Revenue Growth

__timestampPharming Group N.V.Zoetis Inc.
Wednesday, January 1, 2014257624394785000000
Thursday, January 1, 2015118382784765000000
Friday, January 1, 2016166936604888000000
Sunday, January 1, 20171075173355307000000
Monday, January 1, 20181545756115825000000
Tuesday, January 1, 20191893337216260000000
Wednesday, January 1, 20202283946666675000000
Friday, January 1, 20211898530377776000000
Saturday, January 1, 20222056220008080000000
Sunday, January 1, 20232453160008544000000
Monday, January 1, 20249256000000
Loading chart...

Data in motion

A Decade of Revenue Growth: Zoetis Inc. vs. Pharming Group N.V.

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Zoetis Inc. and Pharming Group N.V. have demonstrated contrasting revenue trajectories.

Zoetis Inc.: A Steady Climb

From 2014 to 2023, Zoetis Inc. has shown a remarkable revenue increase of nearly 79%, starting from approximately $4.8 billion in 2014 to an impressive $8.5 billion in 2023. This consistent growth underscores Zoetis's strong market position and strategic expansion in the animal health sector.

Pharming Group N.V.: A Gradual Rise

In contrast, Pharming Group N.V. experienced a more modest revenue growth of around 850% over the same period, from $25.8 million in 2014 to $245.3 million in 2023. While smaller in scale, this growth reflects Pharming's efforts to carve out a niche in the biopharmaceutical landscape.

Both companies highlight the diverse strategies within the pharmaceutical industry, with Zoetis focusing on scale and Pharming on specialized innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025